FDA: is it time for the Watchman? 2

Following its promising debut in the PROTECT-AF trial a few weeks ago at the ACC, the Watchman device appears likely to receive a somewhat less ecstatic response when it appears before the FDA’s Circulatory System Devices Panel on Thursday. The Watchman is an implantable device that blocks the left atrial appendage with a fabric-covered expandable nitinol cage. It is designed to help patients with nonvalvular AF avoid warfarin therapy.

The FDA briefing documents suggest that  difficult questions will be raised at the hearing about the patient population that has been studied with the device, the duration of treatment they received, and the use of concomitant warfarin by some patients.

You can read Reuters, MedPage Today, and Heartwire news reports about the briefing documents.

You can read the FDA briefing documents here.

About these ads

2 comments

  1. Pingback: FDA panel gives cautious nod to the Watchman « CardioBrief

  2. Pingback: FDA: Watchman device will need to wait a bit longer « CardioBrief

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s